Profile data is unavailable for this security.
About the company
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of products that address unmet needs in central nervous system (CNS) disorders and other rare disorders. The Company's lead programs SLS-002 for the treatment of acute suicidal ideation and behavior (ASIB) in depressive disorder (MDD), and SLS-005 for the potential treatment of amyotrophic lateral sclerosis (ALS). SLS-005 for the potential treatment of Sanfilippo Syndromes, which is being explored. It is also developing several preclinical programs, including SLS-010, an oral histamine H3A receptor antagonist that shows promising activity in narcolepsy and related disorders, and SLS-012, an injectable therapy for post-operative pain management. The Company's ongoing programs include SLS-004, SLS-006, SLS-007 and SLS-008.
- Revenue in USD (TTM)0.00
- Net income in USD-73.35m
- Incorporated1987
- Employees15.00
- LocationSeelos Therapeutics Inc300 PARK AVENUE, 2ND FLOORNEW YORK 10022United StatesUSA
- Phone+1 (646) 293-2100
- Fax+1 (858) 436-8155
- Websitehttps://seelostherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Portage Biotech Inc | 0.00 | -15.53m | 109.63m | 6.00 | -- | 0.7159 | -- | -- | -1.16 | -1.16 | 0.00 | 9.04 | 0.00 | -- | -- | 0.00 | -8.93 | 11.61 | -11.77 | 15.79 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -6.55 | -- | -- | -- |
| Solarwindow Technologies Inc | 0.00 | -5.76m | 110.12m | 7.00 | -- | 10.87 | -- | -- | -0.1082 | -0.1082 | 0.00 | 0.1905 | 0.00 | -- | -- | 0.00 | -46.39 | -76.49 | -46.92 | -78.55 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.55 | -- | 101.47 | -- |
| Shattuck Labs Inc | 32.03m | -61.46m | 110.19m | 85.00 | -- | 0.4952 | -- | 3.44 | -1.45 | -1.45 | 0.7572 | 5.25 | 0.1114 | -- | -- | 376,800.00 | -21.37 | -- | -22.94 | -- | -- | -- | -191.90 | -- | -- | -55.80 | 0.00 | -- | 202.16 | -- | -22.87 | -- | -- | -- |
| Greenwich Lifesciences Inc | 0.00 | -5.94m | 111.95m | 3.00 | -- | 6.57 | -- | -- | -0.4526 | -0.4526 | 0.00 | 1.33 | 0.00 | -- | -- | 0.00 | -25.27 | -- | -25.75 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -145.34 | -- | -- | -- |
| Seelos Therapeutics Inc | 0.00 | -73.35m | 112.03m | 15.00 | -- | 4.25 | -- | -- | -0.7015 | -0.7015 | 0.00 | 0.247 | 0.00 | -- | -- | 0.00 | -102.60 | -190.52 | -121.48 | -336.13 | -- | -- | -- | -40,434.13 | -- | -248.42 | 0.4234 | -- | -- | -- | -245.78 | -- | -- | -- |
| XBiotech Inc | 11.05m | -26.77m | 112.63m | 96.00 | -- | 0.4403 | -- | 10.19 | -0.8822 | -0.8822 | 0.3646 | 8.40 | 0.0356 | -- | 1.07 | 113,907.20 | -8.63 | 40.42 | -8.80 | 42.65 | 76.69 | -- | -242.26 | 938.77 | -- | -13.27 | 0.00 | 0.00 | -58.19 | -- | -55.19 | -- | -24.01 | -- |
| Nuvectis Pharma Inc | 0.00 | -13.44m | 112.64m | 8.00 | -- | 8.51 | -- | -- | -28.99 | -28.99 | 0.00 | 0.9043 | 0.00 | -- | -- | 0.00 | -125.31 | -- | -146.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -128,800.00 | -- | -- | -- |
| Praxis Precision Medicines Inc | 0.00 | -232.20m | 113.03m | 139.00 | -- | 0.8139 | -- | -- | -5.14 | -5.14 | 0.00 | 3.05 | 0.00 | -- | -- | 0.00 | -86.98 | -- | -96.83 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -137.56 | -- | -- | -- |
| Athira Pharma Inc | 0.00 | -77.33m | 113.83m | 34.00 | -- | 0.4057 | -- | -- | -1.99 | -1.99 | 0.00 | 7.42 | 0.00 | -- | -- | 0.00 | -23.72 | -- | -24.36 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -174.88 | -- | -- | -- |
| F-Star Therapeutics Inc | 20.80m | -37.13m | 113.97m | 84.00 | -- | 1.59 | -- | 5.48 | -1.75 | -1.75 | 0.991 | 3.32 | 0.1844 | -- | 5.69 | 247,631.00 | -32.91 | -40.73 | -37.07 | -46.31 | -- | -- | -178.51 | -405.68 | -- | -6.95 | 0.1198 | -- | 88.05 | 126.89 | -22.11 | -- | 25.31 | -- |
| Vaccitech PLC - ADR | 32.10m | -1.38m | 114.25m | 72.00 | 132.27 | 0.4491 | 162.29 | 3.56 | 0.0232 | 0.0232 | 0.8673 | 6.84 | 0.1178 | -- | 3.76 | 445,819.40 | -0.5425 | -- | -0.5649 | -- | -- | -- | -4.60 | -- | -- | -- | 0.00 | -- | -94.44 | -- | -187.27 | -- | -- | -- |
| INmune Bio Inc | 356.00k | -32.87m | 114.32m | 10.00 | -- | 1.63 | -- | 321.11 | -1.85 | -1.85 | 0.02 | 3.90 | 0.0048 | -- | 0.087 | 35,600.00 | -44.27 | -41.95 | -45.90 | -43.71 | -- | -- | -9,233.15 | -33,028.86 | -- | -17.32 | 0.1724 | -- | 1,557.51 | -- | -150.76 | -- | -- | -- |
| Gamida Cell Ltd | 0.00 | -89.24m | 114.56m | 166.00 | -- | 14.59 | -- | -- | -1.50 | -1.50 | 0.00 | 0.1309 | 0.00 | -- | -- | 0.00 | -60.55 | -61.18 | -71.44 | -70.92 | -- | -- | -- | -- | -- | -13.89 | 0.9015 | -- | -- | -- | -45.83 | -- | 121.24 | -- |
| TFF Pharmaceuticals Inc | 157.44k | -35.85m | 115.03m | 4.00 | -- | 4.79 | -- | 730.64 | -1.41 | -1.41 | 0.0062 | 0.9435 | 0.0037 | -- | 0.0745 | -- | -84.29 | -- | -89.96 | -69.15 | -- | -- | -22,771.06 | -74,293.30 | -- | -- | 0.00 | -- | -- | -- | -67.17 | -- | -- | -- |
Data as of Sep 29 2022. Currency figures normalised to Seelos Therapeutics Inc's reporting currency: US Dollar USD
22.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Tontine Associates LLCas of 30 Jun 2022 | 4.91m | 4.60% |
| The Vanguard Group, Inc.as of 30 Jun 2022 | 4.89m | 4.59% |
| Horizons ETFs Management (Canada), Inc.as of 30 Jun 2022 | 2.58m | 2.42% |
| Uniplan Investment Counsel, Inc.as of 30 Jun 2022 | 2.50m | 2.34% |
| Group One Trading LPas of 30 Jun 2022 | 2.32m | 2.18% |
| BlackRock Fund Advisorsas of 30 Jun 2022 | 1.78m | 1.67% |
| Millennium Management LLCas of 30 Jun 2022 | 1.59m | 1.49% |
| Woodline Partners LPas of 30 Jun 2022 | 1.16m | 1.09% |
| Renaissance Technologies LLCas of 30 Jun 2022 | 1.15m | 1.08% |
| Geode Capital Management LLCas of 30 Jun 2022 | 1.00m | 0.94% |
More ▼
Data from 30 Jun 2022 - 30 Jun 2022Source: FactSet Research Systems Inc.
